The World Market for Orphan Drugs - KALB-TV News Channel 5 & CBS 2

The World Market for Orphan Drugs

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

The World Market for Orphan Drugs

http://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.html

In recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S., Europe, Japan and globally. With over 400 pages of market analysis and over 120 figures and tables, the report provides in-depth coverage of key competitors and important trends and challenges for makers of orphan drug treatments.

Osteoporosis, arthritis, Alzheimer's, and Parkinson's are major factors affecting quality of life. Mortality from cancer, diabetes, liver and kidney diseases has been slow to change, offering significant areas for research breakthroughs. Cancer, poorly served by traditional chemotherapies, is a major opportunity for biotech firms because the investment compared to return can be favorable: the field has high priority with regulatory authorities who are willing to give it fast track status on the basis of smaller (and therefore cheaper) clinical trials (a few extra months of survival could be enough to win FDA approval); the clinical community is highly concentrated; and the market size is often larger than the approved indication because of a high off-label use (for other cancers). Infectious diseases, the third most common cause of death in many geographic regions, highlight the pressing need for new therapies with novel mechanisms of action to avoid growing issues affecting this industry including a top area of concern-drug resistance.

This report provides estimates for the world market for orphan drugs, as well as the E.U. and Japan markets. Given the size of the U.S. opportunity, the report offers in-depth market data for the U.S. market.

Several segments are discussed, including:

• Oncology
• Hematology
• Musculoskeletal
• Neurology
• Endocrine
• Metabolic
• Others

These segments are the most common areas of development and success for orphan drug developers/marketers which required providing detailed information about these orphan drug market segments.

In the U.S., a drug may be designated an orphan drug if the disease or condition for which it is indicated, affects less than 200,000 Americans. Orphan medicinal products in the E.U. member states are intended for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons. In Japan an orphan drug may be designated for a patient population of less than 50,000 and provide for an unmet medical need. Other countries have similar designations. These three regional markets for drugs are examined in separate sections of the report.

Analysis of The "Pure" Orphan Drug Market

Some publicized estimates of orphan drug markets include brand revenue that is not truly related to the orphan status of the drug. In this unique research effort, Kalorama Information separates strictly orphan revenue from total brand revenue where necessary to provide a true picture of the pure orphan drug market opportunity. The world orphan drug market is difficult to determine due to the variances in orphan drug status and requirements by country. Products may be available as an orphan drug on one country and be a traditional marketing approval for another country. In addition, some products gain orphan status, are granted approval and then removed from the orphan drug database at the request of the developer. There are a number of factors involved, including reimbursement by country, regulation by country, disease status by country and general development by country.

For this market research report, market numbers discussed in this report are focused on the global market in brief with in-depth market coverage of the U.S. market. Additionally, there is select coverage for the European Union and Japanese market. All sales are displayed at the manufacturers' level in U.S. dollars.

This report includes orphan drugs. In cases where sales are generated by indications for both orphan indications and non-orphan indications, we have attempted to extract just the orphan portion of sales. The base year is 2012, with forecasts provided for each year through 2017. The market was generated using estimates of individual product sales and compared with market data from a combination of other methods including disease prevalence trends, population trends, pricing trends, government regulations and reimbursements. Both primary and secondary sources were consulted in developing market estimates.

Demographics, Costs, Regulation and Other Trends Examined

The list of trends and factors affecting the orphan drug market remain lengthy. The orphan drug market is affected by both trends that affect the pharmaceutical industry as a whole and trends that specifically affect the orphan drug market:

• Orphan drug pricing
• Aging of the population
• Increasing life expectancy
• Trends in birth rates
• Cost effectiveness
• Regulatory environments
• Orphan drug incentives
• Population demographics
• Product availability by country/region

Due to the wide variety of products to receive orphan designations, there are numerous developers with products in this area. Some of the developers that have received an orphan designation have followed through to receive a full product approval but others may not gain additional approvals.
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology

Market Segments


Issues and Trends
World Market Summary
Competitors

CHAPTER TWO: INTRODUCTION
Overview
History of the U.S. Orphan Drug Market
Pharmaceutical Research & Development Overview
Pharmaceutical Industry Important Regulatory Terms
Diseases and Orphan Drug Impact
Disease Descriptions

Blood Disorders
Cancer
Hormone Disorders
Infectious Diseases


The Cost Side of Orphan Drugs

CHAPTER THREE: U.S. ORPHAN DRUGS
Overview
Recent Orphan Drug Designations
Orphan Drug Approvals by Company

Abbott Laboratories
Acorda Therapeutics
Actelion Pharmaceuticals
Aegerion Pharmaceuticals
Alexion Pharmaceuticals
Allergan, Inc.
Amgen
Ariad Pharmaceuticals
Astellas
AstraZeneca
Auxilium Pharmaceuticals, Inc.
Bausch & Lomb
Baxter International
Bayer AG
Biogen IDEC
BioMarin Pharmaceutical, Inc.
Boehringer Ingelheim
Bristol-Myers Squibb
Cangene Corporation
Celgene Corporation
CSL Behring
Eisai Co., Ltd.
Eli Lilly & Company
EMD Serono
Endo Health Solutions, Inc.
(previously Endo Pharmaceuticals, Inc.)
Exelixis, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Grifols, S.A.
Hyperion Therapeutics, Inc.
Incyte Corporation
Ipsen, Inc.
Jazz Pharmaceuticals plc
Johnson & Johnson
KV Pharmaceutical Company
Merck & Company
Novartis
Novo Nordisk
NPS Pharmaceuticals
Octapharma USA, Inc.
Onyx Pharmaceuticals, Inc.
Otsuka Pharmaceutical Co., Inc.
Pacira Pharmaceuticals, Inc.
Pfizer, Inc.
Rare Disease Therapeutics, Inc.
Reckitt Benckiser Group plc
Regeneron Pharmaceuticals, Inc.
Roche
Salix Pharmaceuticals, Inc.
Sanofi
Savient Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Shire Plc
Sigma-Tau Pharmaceuticals, Inc.
Spectrum Pharmaceuticals
Takeda Pharmaceutical Company Ltd.
Talon Therapeutics, Inc.
Teva Pharmaceuticals
United Therapeutics Corporation
Valeant Pharmaceuticals International, Inc.
Vertex Pharmaceuticals, Inc.
ViroPharma, Inc.


CHAPTER FOUR: E.U. ORPHAN DRUGS
Overview
Recent Orphan Drug Designations
Select Company Orphan Drug Activities

Actelion Pharmaceuticals
Adienne Pharma & Biotech
Alexion Pharmaceuticals
Amgen
Bayer AG
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb
Celgene Corporation
Eisai Co., Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline
Novartis
Orphan Europe S.A.R.L.
Pfizer, Inc.
Sanofi
Shire Plc
Vertex Pharmaceuticals, Inc.


CHAPTER FIVE: JAPAN ORPHAN DRUGS
Overview
Recent Orphan Drug Designations
Select Company Orphan Drug Activities

Actelion Pharmaceuticals
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene Corporation
GlaxoSmithKline
Johnson & Johnson
Merck Serono
Mitsubishi Tanabe
Novartis
Pfizer, Inc.
Roche
Sanofi


CHAPTER SIX: COMPETITOR TRENDS AND PRACTICES
Acquisitions and Agreements
U.S. Competitor Market Analysis

Amgen
Roche
Celgene
Novartis
Abbott
Biogen Idec
Bayer
Eli Lilly
Bristol-Myers Squibb
Novo Nordisk
Sanofi
Allergan
Other Companies


CHAPTER SEVEN: ORPHAN DRUG INDUSTRY TRENDS
Introduction
U.S. Regulation Shaping the Orphan Drug Segment

Orphan Drug Act of 1983
Rare Disease Act of 2002


Office of Orphan Products Development
Humanitarian Use Device Program
Positives and Negatives of the Orphan Drug Designation

Orphan Drug Designation in the U.S.
Orphan Drug Designation in the E.U.
Orphan Drug Designation in Japan
Orphan Drug Designation in Canada
Orphan Drug Designation in Australia


Factors Affecting the Health Industry

Aging of the Population


Population Statistics

Global Population Trends

Global Population over 65


U.S. Population Trends

U.S. Population over 65
Global Trends in Life Expectancy
Global Trends in Birth Rates




Global Healthcare Spending Trends

General Economic Trends by Country


U.S. Health Industry Trends

U.S. Healthcare Challenges
Economic Trends in the U.S.
U.S. Health Expenditures by Type


CHAPTER EIGHT: U.S. ORPHAN DRUG MARKET SIZE AND OPPORTUNITY
Overview
Market Size and Forecast
Markets by Product Classification

Oncology

Suppliers Market Share


Hematology

Suppliers Market Share


Musculoskeletal

Suppliers Market Share


Neurology

Suppliers Market Share


Endocrinology

Suppliers Market Share


Metabolic

Suppliers Market Share


Others

Suppliers Market Share




CHAPTER NINE: WORLD MARKET SUMMARY? ORPHAN DRUGS
Overview
Market Distribution: United States and World Markets
CHAPTER TEN: CORPORATE PROFILES
Introduction
Orphan Drug Designations by Company: A U.S. Analysis
Company Profiles
Abbott Laboratories

Company Overview
Performance Review


AbbVie

Company Overview
Performance Review


Actelion

Company Overview
Performance Review
Overview
Performance Review


Astellas

Company Overview
Performance Review


AstraZeneca

Company Overview
Performance Review


Baxter

Company Overview
Performance Review


Bayer

Company Overview
Performance Review


Bio Products Laboratory

Company Overview
Biogen Idec
Company Overview
Performance Review


BioMarin

Company Overview
Performance Review


Boehringer Ingelheim

Company Overview
Performance Review


Bristol-Myers Squibb

Company Overview
Performance Review


Cangene

Company Overview
Performance Review


Celgene

Company Overview
Performance Review


CSL Behring

Company Overview
Performance Review


Depomed

Company Overview
Performance Review


Eisai

Company Overview
Performance Review


Eli Lilly

Company Overview
Performance Review


EMD Serono

Company Overview
Performance Review


Exelixis

Company Overview
Performance Review


Gilead Sciences

Company Overview
Performance Review


GlaxoSmithKline

Company Overview
Performance Review


ImmunoGen

Company Overview
Performance Review


Insmed

Company Overview
Performance Review


Johnson & Johnson

Company Overview
Performance Review


LUITPOLD

Company Overview
Performance Review


Merck & Co

Company Overview
Performance Review


Millennium Pharmaceuticals

Company Overview
Performance Review


NBI Pharmaceuticals

Company Overview


Novartis

Company Overview
Performance Review


Novo Nordisk

Company Overview
Performance Review


NPS Pharmaceuticals

Company Overview
Performance Review


Pfizer

Company Overview
Performance Review


Roche

Company Overview
Performance Review


Sanofi

Company Overview
Performance Review


Seattle Genetics

Company Overview
Performance Review


Shire

Company Overview
Performance Review


Sigma Tau

Company Overview
Performance Review


Soligenix

Company Overview
Performance Review


Spectrum

Company Overview
Performance Review


Swedish Orphan Biovitrum

Company Overview
Performance Review


TEVA

Company Overview
Performance Review


United Therapeutics

Company Overview
Performance Review


Valeant

Company Overview
Performance Review


XenoPort

Company Overview
Performance Review


REGULATORY AUTHORITIES AND ORGANIZATIONS
LIST OF COMPANIES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1

World Orphan Drug Market 2007-2017


Figure 1-1: World Orphan Drug Market
CHAPTER TWO: INTRODUCTION
Table 2-1

Phases of Clinical Drug Development


Table 2-2

Total Cancer Incidence by Sex and Country


Figure 2-1

Total Cancer Incidence by Sex and Country


Table 2-3

Average Annual Drug Costs to Patients, Selected Drugs


Figure 2-2

Average Annual Drug Costs to Patients, Selected Drugs


CHAPTER THREE: U.S. ORPHAN DRUGS
Table 3-1

Orphan Drug Designations Granted and Approvals by the FDA 1983-2013*


Figure 3-1

Orphan Drug Designations Granted and Approvals by the FDA 1983-2013*


Table 3-2

12-Months Orphan Drug Designations Granted by FDA (May 1, 2012 - May 1, 2013)


Figure -3-2

May 2012 - May 2013 FDA Orphan Drug Designations by Target Classification


Table 3-3

Abbott Laboratories' Orphan Drug Approvals Granted by FDA


Table 3-4

Acorda Therapeutics' Orphan Drug Approvals Granted by FDA


Table 3-5

Actelion Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-6

Aegerion Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-7

Alexion Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-8

Allergan's Orphan Drug Approvals Granted by FDA


Table 3-9

Amgen's Orphan Drug Approvals Granted by FDA


Table 3-9 (continued)

Amgen's Orphan Drug Approvals Granted by FDA


Table 3-10

Ariad Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-11

Astellas' Orphan Drug Approvals Granted by FDA


Table 3-12

AstraZeneca's Orphan Drug Approvals Granted by FDA


Table 3-13

MedImmune's Orphan Drug Approvals Granted by FDA


Table 3-14

Auxilium Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-15

Bausch & Lomb's Orphan Drug Approvals Granted by FDA


Table 3-16

Baxter International's Orphan Drug Approvals Granted by FDA


Table 3-17

Bayer's Orphan Drug Approvals Granted by FDA


Table 3-18

Biogen IDEC's Orphan Drug Approvals Granted by FDA


Table 3-19

BioMarin Pharmaceutical's Orphan Drug Approvals Granted by FDA


Table 3-20

Boehringer Ingelheim's Orphan Drug Approvals Granted by FDA


Table 3-21

Bristol-Myers's Orphan Drug Approvals Granted by FDA


Table 3-22

Cangene's Orphan Drug Approvals Granted by FDA


Table 3-23

Celgene Corporation's Orphan Drug Approvals Granted by FDA


Table 3-24

CSL Behring's Orphan Drug Approvals Granted by FDA


Table 3-25

Eisai's Orphan Drug Approvals Granted by FDA


Table 3-26

Eli Lilly's Orphan Drug Approvals Granted by FDA


Table 3-27

EMD Serono's Orphan Drug Approvals Granted by FDA


Table 3-28

Endo Health Solutions' Orphan Drug Approvals Granted by FDA


Table 3-29

Exelixis' Orphan Drug Approvals Granted by FDA


Table 3-30

Gilead Sciences' Orphan Drug Approvals Granted by FDA


Table 3-31

GlaxoSmithKline's Orphan Drug Approvals Granted by FDA


Table 3-32

Grifols' Orphan Drug Approvals Granted by FDA


Table 3-33

Hyperion Therapeutics' Orphan Drug Approvals Granted by FDA


Table 3-34

Incyte Corporation's Orphan Drug Approvals Granted by FDA


Table 3-35

Ipsen's Orphan Drug Approvals Granted by FDA


Table 3-36

Jazz Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-37

Johnson & Johnson Pharmaceutical's Orphan Drug Approvals Granted by FDA


Table 3-38

Alza's Orphan Drug Approvals Granted by FDA


Table 3-39

Janssen's Orphan Drug Approvals Granted by FDA


Table 3-40

KV Pharmaceutical's Orphan Drug Approvals Granted by FDA


Table 3-41

Merck & Co.'s Orphan Drug Approvals Granted by FDA


Table 3-41 (continued)

Merck & Co.'s Orphan Drug Approvals Granted by FDA


Table 3-42

Novartis' Orphan Drug Approvals Granted by FDA


Table 3-43

Alcon's Orphan Drug Approvals Granted by FDA


Table 3-44

Novo Nordisk's Orphan Drug Approvals Granted by FDA


Table 3-45

NPS Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-46

Octapharma's Orphan Drug Approvals Granted by FDA


Table 3-47

Onyx Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-48

Otsuka Pharmaceutical's Orphan Drug Approvals Granted by FDA


Table 3-49

Pacira Pharmaceutical's Orphan Drug Approvals Granted by FDA
Table 3-49
Pfizer's Orphan Drug Approvals Granted by FDA


Table 3-49 (continued)

Pfizer's Orphan Drug Approvals Granted by FDA


Table 3-50

Rare Disease Therapeutics' Orphan Drug Approvals Granted by FDA


Table 3-51

Reckitt Benckiser's Orphan Drug Approvals Granted by FDA


Table 3-52

Regeneron Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-53

Roche's Orphan Drug Approvals Granted by FDA


Table 3-54

Genentech's Orphan Drug Approvals Granted by FDA


Table 3-55

Salix Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-56

Sanofi's Orphan Drug Approvals Granted by FDA


Table 3-57

Genzyme's Orphan Drug Approvals Granted by FDA


Table 3-58

Savient Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-59

Seattle Genetics' Orphan Drug Approvals Granted by FDA


Table 3-60

Shire's Orphan Drug Approvals Granted by FDA


Table 3-61

Sigma Tau's Orphan Drug Approvals Granted by FDA


Table 3-62

Spectrum Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-63

Millennium Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-64

Talon Therapeutics' Orphan Drug Approvals Granted by FDA


Table 3-65

Teva's Orphan Drug Approvals Granted by FDA


Table 3-66

Cephalon's Orphan Drug Approvals Granted by FDA


Table 3-67

United Therapeutics' Orphan Drug Approvals Granted by FDA


Table 3-68

Valeant Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-69

Vertex Pharmaceuticals' Orphan Drug Approvals Granted by FDA


Table 3-70

ViroPharma's Orphan Drug Approvals Granted by FDA



CHAPTER FOUR: E.U. ORPHAN DRUGS
Table 4-1

Orphan Drug Designations and Approvals Granted by the EMA 2000-2013*


Figure 4-1

Orphan Drug Designations and Approvals Granted by the EMA 2000-2013*


Figure 4-2

Orphan Drugs Approved by EMA by Target Category


Table 4-2

Orphan Drug Designations Granted by EMA (January 1, 2012 - December 31, 2012)


Figure -4-3

2012 European Union Orphan Drug Designations by Target Classification


Table 4-3

Orphan Drug Designations Granted by EMA (2013, January - April)


CHAPTER FIVE: JAPAN ORPHAN DRUGS
Table 5-1

Orphan Drug Designations and Approvals Granted by the MHLW 1993-2012*


Figure 5-1

Orphan Drug Designations and Approvals Granted by the MHLW 1993-2012*


Figure 5-2

Orphan Drugs Approved by MHLW by Target Category


Table 5-2

Orphan Drug Designations Granted by MHLW (January 1, 2012 - November 14, 2012)


Figure 5-3

2012 Ministry of Health, Labour, and Welfare Orphan Drug Designations by Target Classification


CHAPTER SIX: COMPETITOR TRENDS AND PRACTICES
Figure 6-1

Amgen's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-2

Roche's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-3

Celgene's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-4

Novartis' Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-5

Abbott's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-6

Biogen Idec' Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-7

Bayer's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-8

Eli Lilly's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-9

Bristol-Myers' Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-10

Novo Nordisk's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-11

Sanofi's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Figure 6-12

Allergan's Orphan Drug Sales as a Percentage of Total Prescription Drug Sales, United States


Table 6-1

Competitor Analysis, U.S. Orphan Drug Market, 2012


Figure 6-13

Competitor Analysis, U.S. Orphan Drug Market, 2012


CHAPTER SEVEN: ORPHAN DRUG INDUSTRY TRENDS
Table 7-1

The Global Population, 1980-2050


Figure 7-1

The Global Population, 1980-2050


Table 7-2

Global Population Trends Age 65+, 2000-2050


Figure 7-2

Global Population Trends Age 65+, 2000-2050


Table 7-3

The U.S. Population, 1980-2050


Figure 7-3

The U.S. Population, 1980-2050


Table 7-4

Percent U.S. Population Over Age 65 by Year, 2000-2050


Figure 7-4

United States Population Trend Age 65+, 2000-2050


Table 7-5

Average Life Expectancy in Years by Country 1980 and 2012


Figure 7-5




Average Life Expectancy in Years by Country 1980 and 2012
Table 7-6

Crude Birth Rate per 1,000 Persons 2000, 2005, 2010, Estimated 2012 and Projected 2020


Figure 7-6

Crude Birth Rate per 1,000 Persons 2000, 2005, 2010, Estimated 2012 and Projected 2020


Table 7-7

Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2010209


Figure 7-7

Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2010210


Table 7-8

Average Annual Growth of GDP by Country 2007-2011


Table 7-9

National Healthcare Expenditures in the United States 1960-2020


Table 7-10

National Health Expenditure Amounts, by Type of Expenditure: Calendar Years 2015- 2021


CHAPTER EIGHT: U.S. ORPHAN DRUG MARKET SIZE AND OPPORTUNITY
Table 8-1

The U.S. Orphan Drug Market 2007-2017


Figure 8-1: U.S. Orphan Drug Market
Figure 8-2

Distribution of Sales by Product Classification for Approved
U.S. Orphan Drugs, 2012


Table 8-2

The U.S. Market for Orphan Drugs with Oncology Targets 2007-2017


Figure 8-3

The U.S. Market for Orphan Drugs with Oncology Targets 2007-2017


Figure 8-4

Distribution of Sales for Orphan Drugs with Oncology Targets by Supplier, 2012


Table 8-3

The U.S. Market for Orphan Drugs with Hematology Targets 2007-2017


Figure 8-5

The U.S. Market for Orphan Drugs with Hematology Targets 2007-2017


Figure 8-6

Distribution of Sales for Orphan Drugs with Hematology Targets by Supplier, 2012


Table 8-4

The U.S. Market for Orphan Drugs with Musculoskeletal Targets 2007-2017


Figure 8-7

The U.S. Market for Orphan Drugs with Musculoskeletal Targets 2007-2017


Figure 8-8

Distribution of Sales for Orphan Drugs with Musculoskeletal Targets by Supplier, 2012


Table 8-5

The U.S. Market for Orphan Drugs with Neurology Targets 2007-2017


Figure 8-9

The U.S. Market for Orphan Drugs with Neurology Targets 2007-2017


Figure 8-10

Distribution of Sales for Orphan Drugs with Neurology Targets by Supplier, 2012


Table 8-6

The U.S. Market for Orphan Drugs with Endocrinology Targets 2007-2017


Figure 8-11

The U.S. Market for Orphan Drugs with Endocrinology Targets 2007-2017


Figure 8-12

Distribution of Sales for Orphan Drugs with Endocrinology Targets by Supplier, 2012


Table 8-7

The U.S. Market for Orphan Drugs with Metabolic Targets 2007-2017


Figure 8-13

The U.S. Market for Orphan Drugs with Metabolic Targets 2007-2017


Figure 8-14

Distribution of Sales for Orphan Drugs with Metabolic Targets by Supplier, 2012


Table 8-8

The U.S. Market for Orphan Drugs with Other Disease Targets 2007-2017


Figure 8-15

The U.S. Market for Orphan Drugs with Other Disease Targets 2007-2017


Figure 8-16

Distribution of Sales for Orphan Drugs with Other Disease Targets by Supplier, 2012252


CHAPTER NINE: WORLD MARKET SUMMARY? ORPHAN DRUGS
Table 9-1

World Orphan Drug Market 2007-2017


Figure 9-1: World Orphan Drug Market .Share By Competitor
Table 9-2

World Orphan Drug Market: Distribution by United States and Rest of World, 2007- 2017


Figure 9-2

World Orphan Drug Market: Distribution by United States and Rest of World, 2007- 2017


Figure 9-3

Orphan Drugs: World Markets by Region, 2012


CORPORATE PROFILES
Figure 10-1

Orphan Drug Designations (FDA) by Company


Figure 10-2

Abbott's Financial Performance, 2010-2012


Figure 10-3

AbbVie's Financial Performance, 2010-2012


Figure 10-3

Actelion's Financial Performance, 2010-2012


Figure 10-4

Amgen's Financial Performance, 2010-2012


Figure 10-5

Astellas' Financial Performance, 2010-2012


Figure 10-6

AstraZeneca's Financial Performance, 2010-2012


Figure 10-7

Baxter's Financial Performance, 2010-2012


Figure 10-7

Bayer's Financial Performance, 2010-2012


Figure 10-8

Biogen's Financial Performance, 2010-2012


Figure 10-9

BioMarin's Financial Performance, 2010-2012


Figure 10-10

Boehringer Ingelheim's Financial Performance, 2010-2012


Figure 10-11

Bristol-Myers Squibb's Financial Performance, 2010-2012


Figure 10-12

Cangene's Financial Performance, 2010-2012


Figure 10-13

Celgene's Financial Performance, 2010-2012


Figure 10-14

CSL Limited's Financial Performance, 2010-2012


Figure 10-15

Depomed's Financial Performance, 2010-2012


Figure 10-16

Eisai Company's Financial Performance, 2010-2012


Figure 10-17

Eli Lilly's Financial Performance, 2010-2012


Figure 10-18

Merck KGaA's Financial Performance, 2010-2012


Figure 10-19

Exelixis' Financial Performance, 2010-2012


Figure 10-20

Gilead's Financial Performance, 2010-2012


Figure 10-21

GlaxoSmithKline's Financial Performance, 2010-2012


Figure 10-22

ImmunoGen's Financial Performance, 2010-2012


Figure 10-23

Insmeds's Financial Performance, 2010-2012


Figure 10-24

Johnson & Johnson's Financial Performance, 2010-2012


Figure 10-25

Daiichi Sankyo's Financial Performance, 2010-2012


Figure 10-26

Merck & Co.'s Financial Performance, 2010-2012


Figure 10-27

Takeda's Financial Performance, 2010-2012


Figure 10-28

Novartis' Financial Performance, 2010-2012


Figure 10-29

Novo Nordisk's Financial Performance, 2010-2012


Figure 10-30

NPS Pharmaceutical's Financial Performance, 2010-2012


Figure 10-31

Pfizer's Financial Performance, 2010-2012


Figure 10-32

Roche's Financial Performance, 2010-2012


Figure 10-33

Sanofi's Financial Performance, 2010-2012


Figure 10-34

Seattle Genetics' Financial Performance, 2010-2012


Figure 10-35

Shire's Financial Performance, 2010-2012


Figure 10-36

Soligenix' Financial Performance, 2010-2012


Figure 10-37

Spectrum's Financial Performance, 2010-2012


Figure 10-38

Swedish Orphan Biovitrum's Financial Performance, 2010-2012


Figure 10-39

TEVA's Financial Performance, 2010-2012


Figure 10-40

United Therapeutics' Financial Performance, 2010-2012


Figure 10-41

Valeant's Financial Performance, 2010-2012


Figure 10-42

XenoPort's Financial Performance, 2010-2012


REGULATORY AUTHORITIES AND ORGANIZATIONS
LIST OF COMPANIES




Read the full report:
The World Market for Orphan Drugs

http://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

  • Most Popular StoriesMost Popular StoriesMore>>

  • Metro Division conducts anti-prostitution operation

    Metro Division conducts anti-prostitution operation

    Monday, July 21 2014 9:38 AM EDT2014-07-21 13:38:27 GMT
    ALEXANDRIA, La. (KALB News Channel 5) - On July 17, 2014, the Metro Division of the Rapides Parish Sheriff’s Office conducted an operation targeting prostitution in the Alexandria area.The operation focused on internet solicitation for prostitutes at local hotels. More >>
    ALEXANDRIA, La. (KALB News Channel 5) - On July 17, 2014, the Metro Division of the Rapides Parish Sheriff’s Office conducted an operation targeting prostitution in the Alexandria area.The operation focused on internet solicitation for prostitutes at local hotels. More >>
  • Police: Baton Rouge asst. principal arrested

    Police: Baton Rouge asst. principal arrested

    Wednesday, July 23 2014 11:42 AM EDT2014-07-23 15:42:43 GMT
    BATON ROUGE, La. (AP) - Baton Rouge authorities say an assistant principal at Southeast Middle School has been arrested after admitting to investigators he sent nude pictures to a 15-year-old girl one night while he was drunk.More >>
    BATON ROUGE, La. (AP) - Baton Rouge authorities say an assistant principal at Southeast Middle School has been arrested after admitting to investigators he sent nude pictures to a 15-year-old girl one night while he was drunk.More >>
  • Woman accused of battering mayor prepares to head to court

    Woman accused of battering mayor prepares to head to court

    Tuesday, July 22 2014 7:41 PM EDT2014-07-22 23:41:19 GMT
    ALEXANDRIA, La. (KALB News Channel 5) -- An Alexandria woman is pleading for the city to drop a "simple battery" charge against her stemming from an incident at a city council meeting more than a year ago.More >>
    ALEXANDRIA, La. (KALB News Channel 5) -- An Alexandria woman is pleading for the city to drop a "simple battery" charge against her stemming from an incident at a city council meeting more than a year ago.More >>
Powered by WorldNow
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KALB. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.